Tecan Group AG (TECN1N) Stock Price & Analysis
TECN1N Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- MXN 72.13B
- Enterprise Value
- MXN 2.00B
- Total Cash (Recent Filing)
- MXN 224.63M
- Total Debt (Recent Filing)
- MXN 214.32M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Mar 16, 2027 (Est.)
- EPS Estimate
- 75.64
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue Model
The installed base supports repeat consumables, maintenance, software and service purchases after the initial instrument sale. This mix can make revenue less dependent on new capital-equipment orders and deepen customer relationships as laboratory workflows remain automated.
Conservative Leverage
Low leverage provides financial flexibility while Tecan funds operations, transformation initiatives and customer-facing investment. A conservative capital structure can reduce refinancing pressure and help the company absorb earnings volatility without relying heavily on additional borrowing.
Operational Growth Outlook
Above-market local-currency growth, reiterated margin guidance and reaffirmed 2028 targets indicate that management sees a path toward improved scale and profitability. The outlook is supported by demand across biopharma, diagnostics and other automation applications.
Bears Say
Revenue And Earnings Deterioration
Multi-year revenue contraction and the swing to a substantial 2025 net loss indicate that recent operating momentum has not translated into durable reported earnings. This weakens internal funding capacity and raises the execution burden for the recovery plan.
Gross Margin Pressure
The decline in gross margin shows that input costs, inventory effects and external pricing pressures are currently absorbing part of Tecan's revenue growth. Sustained compression would limit operating leverage and make the 2028 margin ambition more dependent on successful restructuring.
Weaker Cash Conversion
Lower operating cash flow alongside higher receivables and inventory indicates weaker cash conversion from current activity. If this persists, it could constrain funding for transformation and product investment even if adjusted profitability improves.
Tecan Group AG News
TECN1N FAQ
What is Tecan Group AG’s market cap?
When is Tecan Group AG’s upcoming earnings report date?
How were Tecan Group AG’s earnings last quarter?
Is Tecan Group AG overvalued?
Does Tecan Group AG pay dividends?
What is Tecan Group AG’s EPS estimate?
How many shares outstanding does Tecan Group AG have?
What happened to Tecan Group AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tecan Group AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Tecan Group AG
Tecan Group AG, established in 1980 and headquartered in Männedorf, Switzerland, specializes in providing cutting-edge laboratory instruments and holistic solutions. The company caters to a broad spectrum of clients, including pharmaceutical and biotechnology corporations, university research departments, and forensic and diagnostic laboratories. Its operations are structured into two principal segments: Life Sciences Business and Partnering Business. Tecan's extensive product portfolio features automated liquid handling systems, microplate readers and washers, various consumables, reagents for Next-Generation Sequencing (NGS), immunoassays, microbodies, and specialized software. Key proprietary solutions include Tecan Laberwax for automated workflows and Resolvex, an intelligent sample preparation system applicable across diverse fields such as genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA. Additionally, Tecan develops and manufactures crucial components—like precision pumps, valves, robotic arms, and developer software—for other laboratory instrument producers serving life science research, diagnostics, and various industrial applications. Its advanced platform-based automation solutions include Synergence, Freedom EVO, and Fluent instruments. The company's global footprint spans Switzerland, other European nations, North America, Asia, and other international markets.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Monica Manotas
- Employees
- 3,000
- Website
- www.tecan.com
- Address
- Seestrasse 103, Männedorf, ZH, 8708, CH
Tecan Group AG (TECN1N) Earnings & Revenues
TECN1N Company Deck
TECN1N Earnings Call
Earnings Call SentimentPositive
The call painted an overall constructive picture: Tecan delivered above-market sales growth in local currencies, maintained a healthy book-to-bill and recorded a resilient adjusted EBITDA margin with underlying profitability improvement. Management confirmed multi-year targets and reported early, tangible benefits from the Rewired transformation alongside strategic AI and geographic initiatives. However, material challenges remain — gross margin compression (material inflation, FX and tariffs), weaker operating cash flow, supply-chain shipment delays (Cavro), upfront transformation and IT costs, and weakness in the Academia & Government end market. On balance, the positive operational momentum, validated guidance and strategic progress outweigh the near-term financial and operational headwinds, but the company must execute Rewired and Elevate while stabilizing cash conversion and margins.
View all MX:TECN1N earnings summaries